AltamarCAM Partners Invests Alongside Cleon Capital in the Italian Company Labomar

Madrid, June 27, 2026 – AltamarCAM Partners, an independent private asset manager with over 22,000 billion in committed investment, has reached an agreement with Cleon Capital to lead the replacement of several family offices, that have held a minority stake alongside Cleon Capital in the Italian nutraceutical company Labomar since 2020.

AltamarCAM Partners will also contribute new funds to the project. With this transaction, AltamarCAM Partners joins the group of international institutional investors and high-net-worth individuals investing in projects led by **Cleon Capital** in Spain and Italy.

Labomar: Innovation and Growth in the Nutraceutical Industry

Labomar is an Italian company with over 140 million euros annual revenue, specialized in the development and production of advanced, customized nutraceutical solutions. Its services range from R&D to the industrial manufacturing of dietary supplements, medical devices, cosmetics, and foods for special medical purposes, ensuring safe, effective, and unique products.

Over the past five years, **Labomar has tripled its revenue** through a combination of organic growth and strategic acquisitions. In this new phase, alongside AltamarCAM, the company will continue to follow the organic and inorganic growth strategy it has pursued since 2020—a strategy that has enabled it to triple sales and accelerate its international expansion through acquisitions in Canada, Spain, and, most recently, Finland.

At the same time, it will continue to invest in its production and logistics infrastructure, expanding its product range and international presence. In this regard, **Nicola Zambon, CEO and founder of Cleon Capital**, states: *"We are proud to have the support of AltamarCAM, which joins a well-established group of more than 100 successful business families and 20 international institutional investors who have placed their trust in us and are supporting the development of our business projects."*

In **2020**, Cleon Capital led a group of Italian investors in acquiring a stake in the company and served as the anchor investor in its initial public offering. Subsequently, in **2023**, the British fund **Charterhouse** led a takeover bid backed by Labomar's founder and Cleon Capital's investors with the aim of spearheading a phase of expansion. In **2024**, Cleon Capital worked alongside Labomar's management team on the acquisition of the Spanish company **Laboratorios Entema**, supporting the growth and internationalization plan spearheaded by Charterhouse, which recently culminated in the acquisition of the Finnish nutraceutical company **Pharmia**.

About AltamarCAM Partners

AltamarCAM Partners is a global private markets investment firm whose primary objective is to provide institutional investors—including insurance companies, pension funds, and financial institutions—as well as high-net-worth individuals with efficient access to investments in unlisted markets: private equity, venture capital, real assets (real estate and infrastructure), and private debt/credit—through a selection of international managers and various strategies (primary, secondary, co-investments, and direct investment).

In addition, the AltamarCAM Group provides independent investment banking and merchant banking services through its subsidiary Altamar Advisory Partners, as well as direct and efficient access to funds managed by a select group of international managers. With offices in Madrid, Cologne, Barcelona, New York, London, Santiago, de Chile, and Munich, it has a team of approximately 300 people. AltamarCAM Partners has accumulated nearly 22,000 billion euros in assets under management from investors.

About Cleon Capital

Cleon Capital is an independent investment and advisory firm that partners with international investors, executives, and entrepreneurs to accelerate the growth of high-potential companies based in Southern Europe. The firm offers solutions that combine flexible capital, an international network of contacts, a long-term strategic vision, and extensive experience in corporate development—both organic and through acquisitions. It has a solid investor base, which includes nearly 100 successful entrepreneurs, high-net-worth individuals, *family offices*, and international institutional investors.

Cleon Capital's current portfolio includes leading European companies such as the Lexer Group, Spain's leading provider of alternative legal services; **Labomar,** a specialist in the research and production of dietary supplements, nutritional supplements, and medical devices; **Gias**, a leading Italian company in the production of plant-based frozen prepared meals; and **ABK Group**, a manufacturer of high-end ceramic surfaces and invisible induction solutions for modern kitchens. Among its notable successes is **Hevo Group**, a "buy-and-build" project divested in 2024, which became Spain's leading producer of shell eggs with revenue exceeding 150 million euros.